AbbVie and DISCO Pharmaceuticals Strike Strategic Collaboration on AND‑Gated Bispecific Therapeutics – Deal Worth Up to USD 2.5 Billion
DISCO Pharmaceuticals ("DISCO") announced a strategic collaboration and option‑to‑license agreement with AbbVie (NYSE: ABBV) to discover and develop novel AND‑gated bispecific therapeutics for solid tumors with high unmet medical need.…

